![](/img/cover-not-exists.png)
Optimal duration of trastuzumab for early HER2-positive breast cancer
Specht, Jennifer M, Davidson, Nancy EVolume:
389
Language:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(17)30322-7
Date:
March, 2017
File:
PDF, 376 KB
english, 2017